Exact Sciences to Participate in May Investor Conferences

Robert W. Baird Growth Stock Conference 2014
Bank of America Merrill Lynch 2014 Healthcare Conference

MADISON, Wis.--()--Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during May.

Kevin T. Conroy, the company’s chairman and chief executive, will make Exact’s presentation at the Baird Growth Stock Conference in Chicago at 12:40 p.m. CT on Wednesday, May 7.

Mr. Conroy also will participate in the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas at 3:40 p.m. PT on Wednesday, May 14.

A live webcast of each presentation will be available through the company’s website at www.exactsciences.com. An archived webcast will be available following the conclusion of each conference.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company’s website at www.exactsciences.com.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expectations concerning our ability to secure and the timing of FDA approval of and reimbursement for our Cologuard test, our estimated reimbursement amounts, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Contacts

The Luminis Group Ltd for Exact Sciences Corp.
Rod Hise, 608-807-4607
rod@luminisgroup.com

Release Summary

Exact Sciences Corp. will present at the Baird and Bank of America Merrill Lynch investor conferences during May.

Sharing

Contacts

The Luminis Group Ltd for Exact Sciences Corp.
Rod Hise, 608-807-4607
rod@luminisgroup.com